Brentuximab vedotin in the treatment of a patient with refractory Hodgkin disease and Proteus syndrome – a case report and discussion

Treatment of patients with refractory Hodgkin lymphoma is a significant issue. We report a patient with Proteus syndrome and relapsed Hodgkin lymphoma, whose remission was finally achieved after brentuximab vedotin therapy, allowing her to receive a haploidentical stem cell transplant. The possible...

Descripción completa

Detalles Bibliográficos
Autores principales: Myakova, Natalia, Smirnova, Nadezhda, Evstratov, Dmitry, Abugova, Yulia, Balashov, Dmitry, Diakonova, Yulia, Konovalov, Dmitry, Skvortsova, Yulia, Maschan, Alexey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527816/
https://www.ncbi.nlm.nih.gov/pubmed/26273462
http://dx.doi.org/10.1002/ccr3.297
Descripción
Sumario:Treatment of patients with refractory Hodgkin lymphoma is a significant issue. We report a patient with Proteus syndrome and relapsed Hodgkin lymphoma, whose remission was finally achieved after brentuximab vedotin therapy, allowing her to receive a haploidentical stem cell transplant. The possible relationship between both disorders was discussed.

Ejemplares similares